Drugs / Personalized neoantigen DNA vaccine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03988283 | Oct 2024 → Mar 2029 expected | central nervous system cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05743595 | Oct 2023 → Apr 2026 overdue | glioblastoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04015700 | Jul 2020 → May 2022 overdue | glioblastoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03122106 | Jan 2018 → Sep 2021 | malignant pancreatic neoplasm | Washington University School of Medicine | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Personalized neoantigen DNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03988283 ↗ |
| Modality | Vaccine | “neoantigen DNA vaccines” NCT03122106 ↗ |
| Route | Intramuscular | “All study injections will be given intramuscularly” NCT03122106 ↗ |